LifeScience Investors Group AG

Overview

LifeScience Investors Group AG is a Swiss-based private equity firm specializing in long-term investments in the pharmaceutical, medical technology, and life science services sectors. The firm focuses on companies or assets with annual sales between €10 million and €300 million, including traditional pharmaceuticals, biopharmaceuticals, specialty pharmaceuticals, diagnostics, medical devices, and related services. LifeScience Investors Group AG also targets companies in special situations, such as strategic non-core carve-outs, restructuring, and succession planning. The firm's investment strategy involves acquiring and managing assets worldwide, with a particular emphasis on onshoring global manufacturing activities into the European and U.S. regulatory environments as part of its 'buy-and-build' strategy. LifeScience Investors Group AG aims to strategically realign acquired companies and lead them to sustainable growth, maintaining entrepreneurial autonomy as a long-term concept. The firm's investors are predominantly independent, high-net-worth private individuals who are capable of assessing the entrepreneurial necessities of an investment in reorganization situations from their own experience. LifeScience Investors Group AG's team consists of qualified partners with experience in entrepreneurial responsibility and consulting. The partners combine experience in a wide range of business areas and functions, making them ideal interlocutors for the management of the portfolio companies. Through direct shareholding in the investment companies, the partners demonstrate their business commitment as individuals and are closely involved in the respective investment. The firm's approach is guided by the goals of sustainable corporate development and long-term viability, focusing on repositioning corporate strategies based on future market opportunities and available core competencies, strengthening existing resources, and adapting company structures and processes to new strategies.

Investment Focus

• Annual sales between €10 million and €300 million
• Companies in special situations (e.g., strategic non-core carve-outs, restructuring, succession planning)
• Focus on pharmaceutical, medical technology, and life science services sectors
• Onshoring global manufacturing activities into European and U.S. regulatory environments
• Sustainable corporate development and long-term viability
• Entrepreneurial autonomy as a long-term concept
• Independent, high-net-worth private investors
• Experience in entrepreneurial responsibility and consulting
• Direct shareholding in investment companies
• Commitment to sustainable corporate development and long-term viability